News

John Amatruda, senior vice president and research head of diabetes and obesity at Merck Research Laboratories, said: “Available Phase III data showed that both efficacy and adverse events

According to the news source, ImClone has refused to comment on the proposed deal but has divulged that it is in talks with a big pharma company. ImClone

The Phase IIa clinical trial, OZ-101, is designed to examine the effectiveness of OREX-003 in mitigating drug-associated weight gain or other metabolic consequences commonly experienced by patients taking

Identity 2 is expected to enroll 1,100 patients, and includes a treatment period of approximately 21 months. An open-label extension will be available to all participants completing the

This DPP HIV 1-2 rapid test has been developed by Chembio with its patented Dual Path Platform technology. Oswaldo Cruz Foundation of Brazil (Fiocruz), which is affiliated with

The administrative and civil settlement agreements also resolve all US Drug Enforcement Administration (DEA) claims related to the company’s controls against the diversion of controlled substances. Without admitting

The transaction was completed on October 1, 2008. The transaction will be financed from existing cash balances and available lines of credit. Upon closing, Hill-Rom expects to benefit

EU marketing approval for Xarelto was received following a review of data from the extensive record clinical program that included three Phase III trials of Xarelto involving nearly

In preclinical models of human breast cancer, Angiolix had a significant anticancer effect in vivo; this effect was enhanced when Angiolix was given in combination with conventional chemotherapy